

1. IMPORTANT NOTICE

[illegible][illegible]

• *Staphylococcus aureus* (Staph aureus) is a Gram positive cocci in clusters. It is a facultative anaerobe and is found in the skin, nose, throat, and in the environment. It is a common cause of skin infections, such as abscesses, boils, and impetigo. It can also cause more serious infections, such as pneumonia, sepsis, and food poisoning.

2. KEY FINANCIALS

2.1 Major financial statements items and financial indicators

	As at 30 September 2022	As at 31 December 2021	Increase/decrease compared to the end of last year (%)
Net assets	1,000,000.00	1,000,000.00	0.00
Net assets attributable to equity holders of the parent	1,000,000.00	1,000,000.00	0.00
Net assets attributable to non-controlling interests	0.00	0.00	0.00

2.2 Non-recurring item

	For the three months from 1 July 2022 to 30 September 2022	For the nine months ended 30 September 2022
Items		
Net assets	1,000,000.00	1,000,000.00
Net assets attributable to equity holders of the parent	1,000,000.00	1,000,000.00
Net assets attributable to non-controlling interests	0.00	0.00
Net assets attributable to equity holders of the parent	1,000,000.00	1,000,000.00
Net assets attributable to non-controlling interests	0.00	0.00
Net assets	1,000,000.00	1,000,000.00
Net assets attributable to equity holders of the parent	1,000,000.00	1,000,000.00
Net assets attributable to non-controlling interests	0.00	0.00
Net assets	1,000,000.00	1,000,000.00
Net assets attributable to equity holders of the parent	1,000,000.00	1,000,000.00
Net assets attributable to non-controlling interests	0.00	0.00

2.3 Changes in major financial statements item and financial indicators and reason thereof

☒ A₁, ..., A_n ☐ N ☐ A₁, ..., A_n

[illegible]

3. SHAREHOLDERS' INFORMATION

3.1 Total number of ordinary shareholders and preferred shareholders with voting rights resumed and shareholding of the top ten shareholders

[illegible]

[illegible]

N , H N , H .

N , H H k .

N , 0 .

N , A .

4. QUARTERLY FINANCIAL STATEMENTS

4.1 Financial Statements

Consolidated Balance Sheet As at 30 September 2022

United Microelectronics Corporation		
United Microelectronics Corporation and Subsidiaries		
Items	As at 30 September 2022	As at 31 December 2021
Current assets:		
Cash and cash equivalents	1,000,000,000.00	1,000,000,000.00
Accounts receivable	1,000,000,000.00	1,000,000,000.00
Prepaid expenses and other receivables	1,000,000,000.00	1,000,000,000.00
Inventory	1,000,000,000.00	1,000,000,000.00
Other current assets	1,000,000,000.00	1,000,000,000.00
Non-current assets:		
Property, plant and equipment	1,000,000,000.00	1,000,000,000.00
Intangible assets	1,000,000,000.00	1,000,000,000.00
Other non-current assets	1,000,000,000.00	1,000,000,000.00
Total assets	1,000,000,000.00	1,000,000,000.00
Current liabilities:		
Accounts payable	1,000,000,000.00	1,000,000,000.00
Other current liabilities	1,000,000,000.00	1,000,000,000.00
Non-current liabilities:		
Long-term debt	1,000,000,000.00	1,000,000,000.00
Other non-current liabilities	1,000,000,000.00	1,000,000,000.00
Total liabilities	1,000,000,000.00	1,000,000,000.00
Equity:		
Share capital	1,000,000,000.00	1,000,000,000.00
Reserves	1,000,000,000.00	1,000,000,000.00
Total equity	1,000,000,000.00	1,000,000,000.00

Items	As at 30 September 2022	As at 31 December 2021
Current liabilities:		
Trade payables	1,000,000.00	1,000,000.00
Other payables	1,000,000.00	1,000,000.00
Accrued expenses	1,000,000.00	1,000,000.00
Provisions	1,000,000.00	1,000,000.00
Other current liabilities	1,000,000.00	1,000,000.00
Non-current liabilities:		
Long-term debt	1,000,000.00	1,000,000.00
Other non-current liabilities	1,000,000.00	1,000,000.00
Owner's equity:		
Share capital	1,000,000.00	1,000,000.00
Reserves	1,000,000.00	1,000,000.00
Other equity	1,000,000.00	1,000,000.00
Total	1,000,000.00	1,000,000.00

For the nine months ended 30 September 2022

[illegible]

Items	For the nine months ended 30 September 2022	For the nine months ended 30 September 2021
V. Net profit (net loss expressed with “-”)	, 0 , , 0.	, , ,0 0.
()		
N		
()		
(→)	, 0 , , 0.	, , ,0 0.
()		
N		
()		
(→)	, 0 , , 0.	, , ,0 0.
VI. Other comprehensive income, net of tax	0, 0 , .	, , , .0
() N		
()		
()	0, 0 , .	, , , .0
()		, , , . 0
()		, , , . 0
()	0, 0 , .	, , , .
()		
()	, 0 , 0 .	, , , . 0
()	, , , . 0	0, , .
VII. Total comprehensive income	, , 0 , .	, , 0 , .
()		
()	, , 0 , .	, , 0 , .
VIII. Earnings per share		
()	0. 0	0. 0
()	0. \	0. 0

2022年9月30日止九个月，本公司实现营业收入人民币1,000,000,000.00元，较2021年9月30日止九个月增加人民币1,000,000,000.00元。

2022年9月30日止九个月，本公司实现净利润人民币1,000,000,000.00元，较2021年9月30日止九个月增加人民币1,000,000,000.00元。

Consolidated Statement of Cash Flow

For the nine months ended 30 September 2022

		U.S. \$ million	
Items	For the nine months ended 30 September 2022	For the nine months ended 30 September 2021	
I. Cash flow from operating activities:			
Net income	\$ 1,000,000.00	\$ 1,000,000.00	
Depreciation and amortization	100,000.00	100,000.00	
Provision for doubtful accounts	10,000.00	10,000.00	
Gain on sale of equipment	(10,000.00)	(10,000.00)	
Change in accounts receivable	(100,000.00)	(100,000.00)	
Change in accounts payable	10,000.00	10,000.00	
Change in accrued liabilities	10,000.00	10,000.00	
Change in income taxes payable	10,000.00	10,000.00	
Change in other assets and liabilities	10,000.00	10,000.00	
Net change in operating assets and liabilities	10,000.00	10,000.00	
Net cash provided by operating activities	\$ 1,200,000.00	\$ 1,200,000.00	
II. Cash flow from investing activities			
Capital expenditures	(100,000,000.00)	(100,000,000.00)	
Proceeds from sale of equipment	10,000,000.00	10,000,000.00	
Net cash used in investing activities	(90,000,000.00)	(90,000,000.00)	
III. Cash flow from financing activities			
Proceeds from issuance of common stock	10,000,000.00	10,000,000.00	
Proceeds from issuance of debt	10,000,000.00	10,000,000.00	
Repayment of debt	(10,000,000.00)	(10,000,000.00)	
Net cash provided by financing activities	10,000,000.00	10,000,000.00	
Net change in cash and cash equivalents	\$ 300,000.00	\$ 300,000.00	
Cash and cash equivalents at beginning of period	\$ 1,000,000.00	\$ 1,000,000.00	
Cash and cash equivalents at end of period	\$ 1,300,000.00	\$ 1,300,000.00	

